A detailed history of Legato Capital Management LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Legato Capital Management LLC holds 5,295 shares of VKTX stock, worth $272,851. This represents 0.04% of its overall portfolio holdings.

Number of Shares
5,295
Previous 4,540 16.63%
Holding current value
$272,851
Previous $240,000 39.58%
% of portfolio
0.04%
Previous 0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$49.84 - $70.47 $37,629 - $53,204
755 Added 16.63%
5,295 $335,000
Q2 2024

Jul 26, 2024

SELL
$47.39 - $80.2 $481,577 - $814,992
-10,162 Reduced 69.12%
4,540 $240,000
Q1 2024

Apr 15, 2024

SELL
$17.4 - $94.5 $315,862 - $1.72 Million
-18,153 Reduced 55.25%
14,702 $1.21 Million
Q4 2023

Jan 16, 2024

BUY
$9.24 - $19.64 $303,580 - $645,272
32,855 New
32,855 $611,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.95B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Legato Capital Management LLC Portfolio

Follow Legato Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legato Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Legato Capital Management LLC with notifications on news.